Short Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Increases By 74.7%

Autolus Therapeutics plc (NASDAQ:AUTL) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 11,900,000 shares, a growth of 74.7% from the June 30th total of 6,810,000 shares. Based on an average trading volume of 1,710,000 shares, the days-to-cover ratio is presently 7.0 days.

Institutional Trading of Autolus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. EWA LLC boosted its stake in Autolus Therapeutics by 40.2% in the 4th quarter. EWA LLC now owns 25,678 shares of the company’s stock valued at $155,000 after purchasing an additional 7,361 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Autolus Therapeutics by 66.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 27,034 shares of the company’s stock valued at $172,000 after acquiring an additional 10,771 shares during the period. EntryPoint Capital LLC lifted its position in shares of Autolus Therapeutics by 113.6% during the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after acquiring an additional 11,456 shares during the period. Privium Fund Management B.V. lifted its position in shares of Autolus Therapeutics by 43.2% during the 1st quarter. Privium Fund Management B.V. now owns 50,058 shares of the company’s stock valued at $319,000 after acquiring an additional 15,091 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at $100,000. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Price Performance

AUTL traded up $0.07 during trading on Friday, hitting $4.67. The stock had a trading volume of 626,708 shares, compared to its average volume of 1,411,487. The company has a 50 day moving average price of $4.02 and a 200-day moving average price of $5.08. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -3.89 and a beta of 2.11. Autolus Therapeutics has a one year low of $2.01 and a one year high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Friday, May 17th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The company had revenue of $10.09 million during the quarter, compared to analyst estimates of $50.00 million. During the same period in the previous year, the business earned ($0.23) EPS. As a group, sell-side analysts predict that Autolus Therapeutics will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Truist Financial boosted their target price on Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a report on Monday, June 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Autolus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $8.70.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.